Frost & Sullivan Recognizes the Outstanding Innovation in Nyxoah's Extremely Small Neuromodulator for Sleep Apnea Patients

Photo - http://photos.prnewswire.com/prnh/20141215/164460

At 20 mm (length) by 2.5 mm (width), Nyxoah's device is by far the smallest and thinnest neuromodulator in the industry. It requires minimal incision, which, in turn, reduces the possibilities of post-surgical infection, scarring and pain.

Competing obstructive sleep apnea treatment technologies use more than one implantable component and, therefore, require related sensors and wires to connect the different components. Such treatment systems are more invasive, painful, time-consuming, and susceptible to failure.

Nyxoah's neuromodulator comprises an implantable device and an external adhesive patch. The flexible implant is the size of a coin, thinner than a few sheets of paper, and features thin contact leads. In a 15 to 30-minute surgical procedure, the implant is surgically placed under the patient's chin, close to the nerves that control the tongue muscles. Before sleeping, the patient places the external adhesive patch (measuring 55mm by 90mm) on the underside of the chin. The patch wirelessly delivers energy to the nerves around the tongue throughout the night, which prevents airway blockage during sleep.

"The implant has minimal to zero risk of migration from the implantation site," said Frost & Sullivan Research Analyst Saju Mathew. "Unlike other implants that need to be surgically replaced every five years, Nyxoah S.A.'s implant has a lifetime of at least 12 years."

Meanwhile, through careful, strategic patent planning, the company has isolated dozens of critical features and then pursued strategies that are most likely to protect the company's value. The patents are designed to work together to provide intellectual property (IP) protection for Nyxoah.

Studies on Nyxoah's potential reveal that more than 87 percent of physicians in the United States, 67 percent of physicians in France, and 75 percent of physicians in Germany believe that its solution could become a first-line treatment option. Patients also rated the product highly because it provides natural sleep (no masks or tubes), demonstrates long-term effectiveness, is mobile, and does not cause side effects such as dry mouth.

"Apart from enabling health benefits, it lowers the economic burden on the patient; reduces other comorbidities such as coronary artery disease, diabetes and hypertension; and improves their quality of life," noted Mathew.

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, increases customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Nyxoah S.A.

Nyxoah is a clinical-stage medical device start-up company headquartered in Brussels Belgium, with R&D facilities there and in Tel Aviv, Israel. Nyxoah was founded in 2009 by Mr. Robert Taub and Dr. Adi Mashiach.

Nyxoah has developed a game-changing neurostimulation implant that effectively treats Obstructive Sleep Apnea (OSA) and snoring while overcoming current challenges. It is tiny, low cost, has low migration risk and low power consumption, and stimulates without direct nerve contact. As a result, implantation is minimally invasive and occurs without the need to expose nerve tissue. Power is delivered wirelessly from a small, daily-use adhesive patch located up to 50mm from the implant. Preloaded for deployment on a delivery tool, Nyxoah expects that a single surgeon will be able to implant the device in an outpatient procedure of 15-30 minutes. Animal and human studies (in progress) are demonstrating extremely promising results, as world-leading opinion leaders already naming it as the emerging market leader and "the future of apnea treatment".

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion

Join Us: Join our community

Subscribe: Newsletter on "the next big thing"

Register: Gain access to visionary innovation

Contact:

Mireya Espinoza
P: +1.210.247.3870
F: +1.210.348.1003
E: [email protected]